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From the Editor’s Desk
THE NOBEL PRIZE AND 
MAINSTREAM MEDICINE
A recent gathering of clinicians was asked: 
“Who won the 2004 Nobel Prize in 
Physiology or Medicine?”. The silence was 
telling. The revelation that it went to two 
US researchers for “their discoveries of 
odorant receptors and the organisation of 
the olfactory system” was greeted with an 
incredulous “Is that so?”. “A Nobel Prize 
on the nose!” was one mischievous 
rejoinder. Obviously, the Nobel Prize was 
not very important to these clinicians. 
Not so for researchers. Many silently 
dream of receiving that call from the 
Karolinska Institute inviting them to join 
the ranks of Nobel laureates in physiology 
or medicine. 
 From 1901, there have been 182 such 
laureates. Up to 1950 there were 57, three 
out of four of whom were European, and 
whose discoveries were mostly aligned with 
clinical medicine. Another 125 have since 
followed. Now, one of every two come from 
the United States, and their discoveries are 
predominantly in basic research and 
somewhat removed from clinical medicine. 
Does this matter? 
In establishing his Foundation, Alfred 
Nobel sought to impart his wealth to people 
“who, during the preceding year, shall have 
conferred the greatest benefits to mankind”. 
This being so, why was the Nobel Prize in 
medicine not awarded to Salk or Sabin for 
their work in preventing polio, which is 
indeed of great benefit to mankind? Or to 
Bradford Hill for his groundbreaking 
concept of the randomised clinical trial, or 
his work with Richard Doll on smoking and 
lung cancer? These, too, have been of 
enormous benefit to mankind. And there 
are many other significant omissions.
If, as in recent times, there is an 
overwhelming preponderance of awards for 
basic research, the Nobel Prize will become 
largely irrelevant to mainstream medicine. 
Surely, there should be a new category — 
a Nobel Prize in Clinical Medicine.
Martin B Van Der Weyden
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Matters arising
Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions
A recent editorial on the safety and recent withdrawal of rofecoxib has stimulated a number of letters
(Med J Aust 2004; 181: 524-525)
Withdraw all 
COX-2-selective drugs
Peter R Mansfield,* Agnés I Vitry,† 
James M Wright‡
* Research Fellow, Department of General Practice, 
University of Adelaide, 34 Methodist Street, Willunga, 
SA 5172; † Senior Lecturer, QUMPPRC, School of 
Pharmacy and Medical Sciences, University of South 
Australia, Adelaide; ‡ Professor, Department of 
Pharmacology & Therapeutics and Medicine, 
University of British Columbia, Vancouver, BC, Canad .
peter.mansfield@adelaide.edu.
TO THE EDITOR: Langton et al claim that
“the celecoxib studies have not demon-
strated an increased risk of thrombosis”.1
However, the European Agency for the Eval-
uation of Medicinal Products concluded that
“there is a trend towards a higher MI [myo-
cardial infarction] risk associated with the
use of celecoxib compared with naproxen
and diclofenac”, and decided that a warning
statement was required for all cycloxygenase
2 (COX-2)-selective drugs.2 It is surprising
that celecoxib may be worse than
diclofenac, because diclofenac is similarly
COX-2-selective as celecoxib.3,4
A retrospective analysis of the full CLASS
study data for people not taking aspirin
found the rates of serious thromboembolic
cardiovascular events were celecoxib 1.4%
and diclofenac 1.6%, as against 0.7% for
ibuprofen.5 These differences were not indi-
vidually statistically significant, but CLASS
was underpowered for cardiovascular
events. However, pooling the results for the
two similarly COX-2-selective drugs versus
ibuprofen reveals a significant difference
(relative risk [RR], 2.1; 95% CI, 1.1–3.9). In
the full CLASS data, celecoxib did not have
a lower rate of complicated ulcers (RR, 0.83;
95% CI, 0.46–1.5) and there was a trend
towards more serious adverse events of all
types (RR, 1.17; 95% CI, 0.99–1.39) than in
the combined ibuprofen and diclofenac
groups.3,6
We conclude that the case against all
COX-2-selective drugs has not been proven
beyond doubt because they have not been
studied adequately. However, on the balance
of probabilities, they are all likely to have a
similar propensity to rofecoxib to increase
thrombotic cardiovascular events to some
extent. This prothrombotic effect may be
reduced by combining them with aspirin,
but then the main gastrointestinal benefit is
likely to be lost,3,4 so use of such combina-
tions is not justified.
Overall, celecoxib is no more effective,
more expensive, no safer (and possibly less
safe) than non-selective drugs. Meloxicam
has not been shown to be any better. COX-
2-selective drugs should not be used unless
a subpopulation can be identified for whom
these drugs have an advantage over the non-
selective drugs. In theory, COX-2-selective
drugs may be useful for a tiny group of
people who are at greater risk of serious
harm from gastrointestinal injury than from
vascular events. However, there is no proven
way to identify such people and there are no
relevant trials to guide us. For example, no
trials have been done in patients with a
history of peptic ulcer.
All COX-2-selective drugs should be
removed from the market until they have
been properly evaluated.
1 Langton PE, Hankey GJ, Eikelboom JW. Cardiovas-
cular safety of rofecoxib (Vioxx): lessons learned
and unanswered questions [editorial]. Med J Aust
2004; 181: 524-525. Previously published online, 26
October 2004. 
2 Celecoxib. Annex II: Overall summary of the scien-
tific evaluation of medicinal products containing
celecoxib, etoricoxib, parecoxib, rofecoxib, or val-
decoxib. London: European Agency for the Evalua-
tion of Medicinal Products, 2004. Available at:
www.emea.eu.int/pdfs/human/referral/celecoxib/
EN%20Celecoxib.pdf (accessed Nov 2004).
3 Wright JM. The double-edged sword of COX-2
selective NSAIDs. Can Med Assoc J 2002; 167:
1131-1137.
4 Fitzgerald GA. Coxibs and cardiovascular disease.
N Engl J Med 2004; 351: 1709-1711.
5 Strand V, Hochberg MC. The risk of cardiovascular
thrombotic events with selective cyclooxygenase-2
inhibitors. Arthritis Rheum 2002; 47: 349-355.
6 Bassett K, Wright JM, Puil L, et al. Cyclooxygenase-
2 inhibitor update: journal articles fail to tell the full
story. Can Fam Physician 2002; 48: 1455-1460. ❏
COX-2 selectivity varies 
across class
Leslie G Cleland,* Michael J James†
* Director, † Chief Medical Scientist, Department 
of Rheumatology, Royal Adelaide Hospital, 
North Terrace, Adelaide, SA 5000 
lcleland@mail.rah.sa.gov.au
TO THE EDITOR: Langton et al document
the history of rofecoxib approval in 1999
and withdrawal in 2004.1 They also provide
an outline of the possible mechanisms for
increased cardiovascular risk, which we
detailed in the Journal in August 2001.2
Their editorial raises the issue of whether
the increased cardiovascular risk is a class
effect of all selective cyclooxygenase 2
(COX-2) inhibitors and notes that no
increased risk has been identified to date
with celecoxib use. While this is correct, the
editorial omits to state that, although several
drugs are categorised as “COX-2 inhibitors”,
the selectivity for COX-2 over COX-1 inhi-
bition varies greatly between different drugs
(see Box).3
It is potentially significant that celecoxib
is only modestly COX-2 selective compared
with rofecoxib. Because COX-2-selective
inhibition can lead to selective inhibition of
vascular prostacyclin synthesis with little or
no effect on vascular or platelet thrombox-
ane synthesis,1 a highly selective COX-2
inhibitor such as rofecoxib is expected to
disrupt the balance between antithrombotic
prostacyclin and prothrombotic thrombox-
ane. The relatively modest COX-2 selectivity
of celecoxib may be one explanation for the
lack of adverse cardiovascular effects dem-
onstrated to date. It would also explain its
lack of upper gastrointestinal tract protec-
tion relative to diclofenac, as both drugs
have similar COX-2 selectivity.4
The newer coxibs, like rofecoxib, are sig-
nificantly more COX-2-selective than
celecoxib and, if this selectivity is the basis
for the adverse cardiovascular events, then
caution is needed with these newer agents.
Although the editorial states that trials have
not shown increased risk with the newer
coxibs, this is not correct. On 15 October
2004, Pfizer announced that valdecoxib,
when used for pain management in coro-
Selectivity for COX-2 for different 
“COX-2 inhibitors”3
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MATTERS ARISINGnary artery bypass surgery, caused an
increased number of adverse cardiovascular
events.5
As the editorial states, the VIGOR study
with rofecoxib in treating rheumatoid arthri-
tis revealed a greatly increased incidence of
adverse cardiovascular events compared
with naproxen, and yet rofecoxib sales con-
tinued for another four years at a high level.1
Perhaps the most important question for
prescribers arising from the experience with
rofecoxib is not whether clinical trial results
are conclusive, but how should prescribers
respond to apparent conflicts in the medical
literature. In such a situation, resort to
ethical and legal obligations for disclosure of
information will be the prudent approach,
as we have detailed.6
For prescribers considering the loss of
rofecoxib, some perspective is provided by
the following. The number needed to treat
(NNT) to cause an increase in one fatal or
non-fatal cardiac event in the VIGOR study
was 225 (average trial duration was 9
months). In trials with statins in which
coronary heart disease was absent at enrol-
ment, the NNT per year to prevent one fatal
or non-fatal coronary event was 217 to
256.7
1 Langton PE, Hankey GJ, Eikelboom JW. Cardiovas-
cular safety of rofecoxib (Vioxx): lessons learned
and unanswered questions [editorial]. Med J Aust
2004; 181: 524-525. Previously published online, 26
October 2004. 
2 Cleland LG, James MJ, Stamp LK, Penglis PS. COX-
2 inhibition and thrombotic tendency: a need for
surveillance. Med J Aust 2001; 175: 214-217.
3 Patrono C, Patrignani P, Garcia-Rodriguez LA.
Cyclooxygenase-selective inhibition of prostanoid
formation: transducing biochemical selectivity into
clinical read-outs. J Clin Invest 2001; 108: 7-13.
4 Juni P, Rutjes AWS, Dieppe PA. Are selective COX-2 
inhibitors superior to traditional non-steroidal anti-
inflammatory drugs? BMJ 2002; 324: 1287-1288.
5 Pfizer provides information to healthcare profes-
sionals about its Cox-2 medicine Bextra® (Val-
decoxib) [press release]. 15 October 2004. Available
at: www.pfizer.com/are/news_releases/2004pr/mn_
2004_1015.html (accessed Nov 2004).
6 James MJ, Cleland LG. Applying a research ethics
committee approach to a medical practice contro-
versy: the case of COX-2 inhibitors. J Med Ethics
2004; 30: 182-184.
7 Kumana CR, Cheung BM, Lauder IJ. Gauging the
impact of statins using number needed to treat.




Hari Manev,* Radmila M Manev†
* Professor, † Assistant Professor of Clinical Psychiatry, 
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Chicago, 1601 West Taylor Street, MC912, 
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TO THE EDITOR: In their editorial on the
rofecoxib controversy, Langton et al point
out that large-scale but inconclusive studies
failed to recognise an increased risk of heart
attack and stroke in patients treated with
this cyclooxygenase 2 (COX-2) inhibitor.1
Might something still be learned from these
studies? Both COX-2 and 5-lipoxygenase (5-
LOX) use the same substrate (arachidonic
acid) to produce prostaglandins and leuko-
trienes, respectively. Overactive 5-LOX
increases the risk of heart attack and
stroke,2,3 and may be involved in the comor-
bidity of these disorders with anxiety and
depression.4 In contrast, COX-2 appears to
be cardioprotective.5
Genetic diversity is responsible for over-
active 5-LOX in some individuals and
increases their risk for cardiovascular
pathology.2,3 It is likely that patients with
these alleles might be more susceptible to
cardiovascular pathology in the absence of
COX-2 activity — that is, be at increased
risk of rofecoxib-provoked myocardial in-
farction and stroke.
If possible, retrospective studies should
be attempted to determine the genotype of
subjects treated with rofecoxib for 5-LOX2
and 5-LOX-activating protein3 polymor-
phisms and to relate these findings to rates
of myocardial infarction and stroke.
1 Langton PE, Hankey GJ, Eikelboom JW. Cardiovas-
cular safety of rofecoxib (Vioxx): lessons learned
and unanswered questions [editorial]. Med J Aust
2004; 181: 524-525. Previously published online, 26
October 2004. 
2 Dwyer JH, Allayee H, Dwyer KM, et al. Arachidonate
5-lipoxygenase promoter genotype, dietary arachi-
donic acid, and atherosclerosis. N Engl J Med 2004;
350: 29-37.
3 Helgadottir A, Manolescu A, Thorleifsson G, et al.
The gene encoding 5-lipoxygenase activating pro-
tein confers risk of myocardial infarction and stroke.
Nat Genet 2004; 36: 233-239.
4 Manev R, Manev H. 5-Lipoxygenase as a putative
link between cardiovascular and psychiatric disor-
ders. Crit Rev Neurobiol 2004; 16: 177-182.
5 FitzGerald GA. Coxibs and cardiovascular disease.
N Engl J Med 2004; 351: 1709-1711. ❏
Paracetamol should be first-
line therapy in osteoarthritis
Richard O Day,* Garry G Graham†
* Professor of Clinical Pharmacology, University of New 
South Wales and St Vincent’s Hospital, Victoria Road, 
Darlinghurst, NSW 2010; † Emeritus Professor of 
Pharmacology, University of New South Wales, 
Sydney, NSW
r.day@unsw.edu.au
TO THE EDITOR: We consider that it is
important to comment on the views
expressed by Langton et al on the limited
value of paracetamol in the treatment of
musculoskeletal pain.1
Langton et al recognise that paracetamol
is widely recommended as first-line therapy
to reduce chronic pain, but they largely
dismiss its usefulness, noting that:
. . . when used alone paracetamol
appears to be less effective than NSAIDs
and there are no studies of the safety of
the long-term intake of paracetamol.1
However, paracetamol is widely recom-
mended as the first-line drug treatment in
the management of osteoarthritis. This is
based on its efficacy and safety as compared
with nonsteroidal anti-inflammatory drugs
(NSAIDs), including cyclooxygenase 2
(COX-2) inhibitors. This position is sup-
ported by published guidelines, including
those of  the American Col lege of
Rheumatology2 and the European League of
Associations of Rheumatology (EULAR).3 In
these guidelines, NSAIDs are recommended
for use in moderate to severe osteoarthritis
pain (American College of Rheumatology
guidelines) or where the pain is unrespon-
sive to paracetamol (EULAR guidelines).
Our own Australian Therapeutic Guideline
series and National Prescribing Service pub-
lications similarly recommend paracetamol
as first-line treatment in osteoarthritis4 (see
National Prescribing Service, Fact Sheet 8,
October 2004 <www.nps.org.au>).
The efficacy of paracetamol in comparison
with NSAIDs in patients with osteoarthritis
has been demonstrated in patients treated
for periods ranging from 3 weeks to 2 years,
with total daily doses of paracetamol rang-
ing from 2.6 g to 4.0 g,5 but this has been
contentious.6,7 In a 2-year study involving
66 patients with osteoarthritis, Williams et
al noted a higher withdrawal rate due to side
effects in the naproxen group than in the
paracetamol group, and slightly less efficacy
in the paracetamol group.5 Pincus and col-
leagues reported that a third of patients
receiving paracetamol continued on this
treatment for more than 24 months, and198 MJA • Volume 182 Number 4 • 21 February 2005
MATTERS ARISINGthat paracetamol was significantly less likely
to be discontinued because of toxicity than
NSAIDs.8 Thus, although paracetamol is on
average less effective in pain reduction com-
pared with NSAIDs,6 the difference in effi-
cacy is small and a substantial proportion of
patients can be treated satisfactorily and
safely with paracetamol alone.9
Paracetamol remains the appropriate ini-
tial treatment for the management of osteo-
arthritis. Other medications, such as
NSAIDs or COX-2 inhibitors, can be added
if patient response is unsatisfactory and the
risk–benefit ratios are acceptable. When
considering alternative options to rofecoxib,
prescribers should also review the non-drug
options, such as weight loss, physiotherapy,
orthotics, and, where possible, opt for para-
cetamol first.10 Prescribers need to continue
to be mindful of the potential for adverse
effects with NSAIDs, particularly in high-
risk patients or patients taking concomitant
medications.
The serious public health problem of
upper gastrointestinal tract bleeding caused
by NSAIDs is a major consideration in the
management of patients with osteoarthritis
and becomes more of an issue in the elderly,
many of whom have osteoarthritis.
Competing interests: Professor Day is a member
of advisory committees on COX-2 inhibitors for
Merck Sharp & Dohme (Aust) Pty Ltd (which mar-
kets rofecoxib and etoricoxib), and previously for
Pfizer Pty Ltd (which markets celecoxib). He is a
member of a general advisory committee of Glaxo-
SmithKline (which markets paracetamol). Glaxo-
SmithKline have supported research projects of
Professor Graham on paracetamol.
1 Langton PE, Hankey GJ, Eikelboom JW. Cardiovas-
cular safety of rofecoxib (Vioxx): lessons learned
and unanswered questions [editorial]. Med J Aust
2004; 181: 524-525. Previously published online, 26
October 2004. 
2 American College of Rheumatology Subcommittee
on Osteoarthritis. Recommendations for the medi-
cal management of osteoarthritis of the hip and
knee: 2000 update. Arthritis Rheum 2000; 43: 1905-
1915.
3 Jordan KM, Arden NK, Doherty M, et al. EULAR
recommendations 2003: an evidence based
approach to the management of knee osteoarthri-
tis: Report of a Task Force of the Standing Commit-
tee for International Clinical Studies Including
Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;
62: 1145-1155.
4 Musculoskeletal pain. In: Therapeutic guidelines.
Analgesic. Version 4, 2002; 133.
5 Williams HJ, Ward JR, Egger MJ, et al. Comparison
of naproxen and acetaminophen in a two-year
study of treatment of osteoarthritis of the knee.
Arthritis Rheum 1993; 36: 1196-1206.
6 Case JP, Baliunas AJ, Block JA. Lack of efficacy of
acetaminophen in treating symptomatic knee oste-
oarthritis: a randomized, double-blind, placebo-
controlled comparison trial with diclofenac sodium.
Arch Intern Med 2003; 163: 169-178.
7 Geba GP, Weaver AL, Polis AB, et al. Efficacy of
rofecoxib, celecoxib, and acetaminophen in oste-
oarthritis of the knee: a randomized trial. JAMA
2002; 287: 64-71.
8 Pincus T, Swearingen C, Cummins P, Callahan LF.
Preference for nonsteroidal antiinflammatory drugs
versus acetaminophen and concomitant use of
both types of drugs in patients with osteoarthritis. J
Rheumatol 2000; 27: 1020-1027.
9 Zhang W, Jones A, Doherty M. Does paracetamol
(acetaminophen) reduce the pain of osteoarthritis?
A meta-analysis of randomised controlled trials.
Ann Rheum Dis 2004; 63: 901-907.
10 Day RO, Graham GG. The vascular effects of COX-2
selective inhibitors. Aust Prescr 2004; 27. 142-145.❏
Cardiovascular safety of 
rofecoxib (Vioxx): lessons 
learned and unanswered 
questions
Paul Langton,* Graeme Hankey,† 
John Eikelboom‡
* Cardiologist, Hollywood Private Hospital, Nedlands, 
WA; † Neurologist, Stroke Unit, ‡ Haematologist, 
Royal Perth Hospital, GPO Box X2213, Perth, WA 6847
john.eikelboom@health.wa.gov.au
IN REPLY: Mansfield, Vitry and Wright take
issue with our statement that the celecoxib
studies have not shown an increased risk of
thrombosis, but provide no data to support
their claims, while Cleland and James high-
light differences in COX-2 selectivity as a
potential explanation for differences in the
cardiovascular safety of coxibs. Recently
published clinical data confirm an increased
risk of cardiovascular events with rofecoxib
but not celecoxib,1 which is consistent with
in-vivo studies suggesting that celecoxib but
not rofecoxib improves endothelial func-
tion,2,3 as well as a significantly lower inci-
dence of oedema and hypertension with
celecoxib compared with rofecoxib.4 Never-
theless, we reiterate that it remains incum-
bent on drug manufacturers and regulatory
authorities to demonstrate cardiovascular
safety for all new and existing coxibs,
including celecoxib.
The published coronary artery bypass
graft surgery randomised trial referred to by
Cleland and James did not report a signifi-
cant excess of adverse cardiovascular events
with valdecoxib,5 nor did two recently pub-
lished meta-analyses.6,7 However, unpub-
lished data from a second coronary artery
bypass graft surgery trial, as well as meta-
analyses presented at the American Heart
Association meeting in New Orleans in
November 2004, indicate that valdecoxib
compared with placebo significantly
increases the risk of adverse cardiovascular
events.8 This is reflected in the recently
revised US prescribing information for
valdecoxib.9
Manev and Manev propose enhanced 5-
lipoxygenase activity as a mechanism for
increased cardiovascular risk in patients
treated with COX-2-selective inhibitors. We
agree that this important hypothesis merits
further study.
Day and Graham emphasise paracetamol
as first-line drug treatment in the manage-
ment of osteoarthritis, referring to recently
published American, European and Austral-
ian guidelines to support their position. We
do not dispute the effectiveness of paraceta-
mol to reduce chronic pain. However, data
from the 2004 systematic review quoted in
our editorial10 demonstrate that nonsteroi-
dal anti-inflammatory drugs are better than
paracetamol for pain relief and are often
preferred by patients, despite a higher inci-
dence of adverse effects. Only one of the 10
randomised controlled trials included in this
systematic review followed patients beyond
3 months; this study reported the primary
efficacy outcome only during the first 6
weeks and was not powered for safety.
1 Kimmel SE, Berlin JA, Reilly M, et al. Patients
exposed to rofecoxib and celecoxib have different
odds of non-fatal myocardial infarction. Ann Intern
Med 2005; 142. Published online 7 Dec 2004. Avail-
able at: www.annals.org (accessed Dec 2004).
2 Chenevard R, Hurlimann D, Bechir M, et al. Selec-
tive COX-2 inhibition improves endothelial function
in coronary artery disease. Circulation 2003; 107:
405-409.
3 Bogaty P, Brophy JM, Noel M, et al. Impact of
prolonged cyclo-oxygenase-2 inhibition on inflam-
matory markers and endothelial function in patients
with ischemic heart disease and raised C-reactive
protein. A randomised placebo-controlled study.
Circulation 2004; 110: 934-939.
4 Whelton A. COX-2-specific inhibitors and the kid-
ney: effect on hypertension and oedema. J Hyper-
tens 2002; 20 Suppl 6: S31-S35.
5 Ott E, Nussmeier NA, Duke PC, et al. Efficacy and
safety of the cyclooxygenase-2 inhibitors parecoxib
and valdecoxib in patients undergoing coronary
artery bypass surgery. J Thorac Cardiovasc Surg
2003; 125: 1481-1492.
6 Edwards JE, McQuay HJ, Moore RA. Efficacy and
safety of Valdecoxib for treatment of osteoarthritis
and rheumatoid arthritis: systematic review of ran-
domised controlled trials. Pain 2004; 111: 286-296.
7 White WB, Strand V, Roberts R, Whelton A. Effects
of the cyclooxygenase-2 specific inhibitor val-
decoxib versus nonsteroidal antiinflammatory
agents and placebo on cardiovascular thrombotic
events in patients with arthritis. Am J Ther 2004; 11:
244-250.
8 Battling Bextra. Meta-analyses could be taken up at





9 New US prescribing information for valdecoxib.
Available at: www.pfizer.com/download/uspi_bex-
tra.pdf (accessed Dec 2004).
10 Zhang W, Jones A, Doherty M. Does paracetamol
(acetaminophen) reduce the pain of osteoarthritis?
A meta-analysis of randomised controlled trials.
Ann Rheum Dis 2004; 63: 901-907. ❏MJA • Volume 182 Number 4 • 21 February 2005 199
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Acute presentation of 
childhood hypothyroidism
Ursula Bayliss,* Christopher Cowell,† 
James Hong,‡ Veronica Wiley,§ 
Bridget Wicken¶
* Clinical Nurse Consultant, §Principal Scientist, 
¶ Clinical Director, NSW Newborn Screening Pro-
gramme, † Head, Institute of Endocrinology & 
Diabetes, The Children's Hospital at Westmead, 
Westmead, NSW 2145; ‡ Paediatrician, North Gosford 
Medical Centre, North Gosford, NSW.
bridgetw@chw.edu.au
TO THE EDITOR: We report an acute
presentation of congenital hypothyroidism
in a child almost 6 years old. The condition
was not detected by newborn screening.
Screening of all neonates started in New
South Wales in July 1977, with thyroid
stimulating hormone (TSH) being measured
in dried blood spots taken from a heel-prick
blood sample (currently at 2–3 days of age).
A whole-blood TSH level of 40 mIU/L or
above triggers a request for full thyroid
function testing, whereas with a level of 20–
39 mIU/L a second sample is requested. We
have screened over 2.3 million babies and
detected 690 babies with congenital
hypothyroidism. Ten babies with dyshor-
monogenesis or ectopic thyroid tissue had
normal results and were missed by the
screening test. Since screening started,
“juvenile hypothyroidism” not associated
with thyroid antibodies has all but disap-
peared.
A healthy girl aged 5 years 11 months
presented with acute dysphagia and drool-
ing. There were no previous dysphagic
symptoms. Initially, epiglottitis was sus-
pected; however, at endoscopy a lingual
thyroid was visualised at the base of her
tongue, and this was confirmed by a techne-
tium scan. She had normal growth and
development, with both height and weight
at the 50th centiles, a pulse rate of 90 beats/
min, and normal deep tendon reflexes.
The whole-blood TSH level at newborn
screening on Day 3 was 40 mIU/L (reference
range [RR], < 20 mIU/L). Thyroid function
testing at another hospital on Day 10
showed a serum TSH level of 16.6 mIU/L
and a serum free thyroxine (FT4) level
within the normal range (12 pmol/L; RR,
11–30 pmol/L). These results were inter-
preted as normal, whereas, in fact, the TSH
level was above the reference range for 10
days of age (< 10mIU/L), although within
the reference range for 2–7 days.
On the patient’s admission for treatment
of acute dysphagia, the TSH level was
10.9 mIU/L and the FT4 level was 18 pmol/
L. A diagnosis was made of compensated
hypothyroidism secondary to the ectopically
placed lingual thyroid. Thyroxine treatment
was commenced on diagnosis, and regular
follow-up arranged. Three months after the
start of treatment, the results of thyroid
function tests (FT4, 17 pmol/L; TSH,
2.7 mIU/L) were within the normal range.
Acute presentation of a lingual thyroid is
most unusual.1 This case emphasises that
further investigations must be performed
when thyroid function test results are equiv-
ocal. Unfortunately, the thyroid status was
considered normal because the FT4 value
was within the normal range. All babies
whose TSH results remain elevated while
the FT4 levels are normal should have a
thyroid scan, as we recommend when
reporting results.
1 Koch CA, Picken C, Clement SC, et al. Ectopic
lingual thyroid: an otolaryngologic emergency
beyond childhood. Thyroid 2000; 10: 511-514. ❏
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